Use

This test aids physicians in the assessment of risk of atrial fibrillation (AF) and cardioembolic stroke. Carriers of risk variants at 4q25 may have up to approximately 1.7‑fold increased risk of AF and up to approximately 1.5‑fold increased risk of cardioembolic stroke related to AF. Developed and performed by Quest Diagnostics Nichols Institute, this CLIA‑certified and CAP‑accredited laboratory test has not been cleared or approved by the FDA. It may help inform clinical follow‑up decisions in patients with potential predisposition to AF.